Loading…
Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
Rey, Jacques, Poitiers, Franck, Paehler, Tobias, Brunet, Aurélie, DiCioccio, A. Thomas, Cannon, Christopher P., Surks, Howard K., Pinquier, Jean‐Louis, Hanotin, Corinne, Sasiela, William J.
Published in Journal of the American Heart Association (01.06.2016)
Published in Journal of the American Heart Association (01.06.2016)
Get full text
Journal Article
Loading…
Loading…
A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
Baruch, Amos, Luca, Diana, Kahn, Robert S., Cowan, Kyra J., Leabman, Maya, Budha, Nageshwar R., Chiu, Cecilia P.C., Wu, Yan, Kirchhofer, Daniel, Peterson, Andrew, Davis Jr, John C., Tingley, Whittemore G.
Published in Clinical cardiology (Mahwah, N.J.) (01.07.2017)
Published in Clinical cardiology (Mahwah, N.J.) (01.07.2017)
Get full text
Journal Article
Loading…
Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
DeVay, Rachel M., Shelton, David L., Liang, Hong
Published in The Journal of biological chemistry (12.04.2013)
Published in The Journal of biological chemistry (12.04.2013)
Get full text
Journal Article
Loading…
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience
Pandey, Amritanshu S, Bajaj, Harpreet S, Garg, Vinay, Pandey, Avinash, Verma, Subodh
Published in Current opinion in cardiology (01.09.2017)
Published in Current opinion in cardiology (01.09.2017)
Get more information
Journal Article
Loading…
Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9
Guo, Yuan-Lin, Liu, Jun, Xu, Rui-Xia, Zhu, Cheng-Gang, Wu, Na-Qiong, Jiang, Li-Xin, Li, Jian-Jun
Published in Clinical drug investigation (01.12.2013)
Published in Clinical drug investigation (01.12.2013)
Get full text
Journal Article
Loading…
Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study
Iannuzzo, Gabriella, Buonaiuto, Alessio, Calcaterra, Ilenia, Gentile, Marco, Forte, Francesco, Tripaldella, Maria, Di Taranto, Maria D., Giacobbe, Carola, Fortunato, Giuliana, Rubba, Paolo O., Di Minno, Matteo N. Dario
Published in Nutrition, metabolism, and cardiovascular diseases (01.03.2022)
Published in Nutrition, metabolism, and cardiovascular diseases (01.03.2022)
Get full text
Journal Article
Loading…
Loading…
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
Lawler, Patrick R., Manvelian, Garen, Coppi, Alida, Damask, Amy, Cantor, Michael N., Ferreira, Manuel A. R., Paulding, Charles, Banerjee, Nilanjana, Li, Dadong, Jorgensen, Susan, Attre, Richa, Carey, David J., Krebs, Kristi, Milani, Lili, Hveem, Kristian, Damås, Jan K., Solligård, Erik, Stender, Stefan, Tybjærg-Hansen, Anne, Nordestgaard, Børge G., Hernandez-Beeftink, Tamara, Rogne, Tormod, Flores, Carlos, Villar, Jesús, Walley, Keith R., Liu, Vincent X., Fohner, Alison E., Lotta, Luca A., Kyratsous, Christos A., Sleeman, Mark W., Scemama, Michel, DelGizzi, Richard, Pordy, Robert, Horowitz, Julie E., Baras, Aris, Martin, Greg S., Steg, Philippe Gabriel, Schwartz, Gregory G., Szarek, Michael, Goodman, Shaun G.
Published in Critical care explorations (08.11.2023)
Published in Critical care explorations (08.11.2023)
Get full text
Journal Article
Loading…
Loading…
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
Mohammadi, Kusha A., Brackin, Taylor, Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Manvelian, Garen, Pordy, Robert, Fazio, Sergio, Geba, Gregory P.
Published in Cancer medicine (Malden, MA) (01.08.2023)
Published in Cancer medicine (Malden, MA) (01.08.2023)
Get full text
Journal Article
Loading…
Loading…
Effects of 12ᅡ weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin
Fazio, Sergio, Robertson, David G, Joh, Tenshang, Wan, Hong, Riel, Tom, gues, Philippe, Baum, Charles M, Garzone, Pamela D, Gumbiner, Barry
Published in Cardiovascular therapeutics (01.02.2018)
Published in Cardiovascular therapeutics (01.02.2018)
Get full text
Journal Article
Loading…
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2[Delta]a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies
Gumbiner, Barry, Joh, Tenshang, Liang, Hong, Wan, Hong, Levisetti, Matteo, Vana, Alicia M, Shelton, David L, gues, Philippe, Billotte, Stephan, Pons, Jaume, Baum, Charles M, Garzone, Pamela D
Published in Cardiovascular therapeutics (01.02.2018)
Published in Cardiovascular therapeutics (01.02.2018)
Get full text
Journal Article
Loading…
Loading…
Abstract 12784: Circulating Mature Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Level Predicts Diminished Response to Statin Therapy in Patients With Coronary Artery Disease
Naoto, Kuyama, Yu, Kataoka, Harada-Shiba, Mariko, Hori, Mika, Ogura, Masatsune, Asaumi, Yasuhide, Noguchi, Teruo, Yasuda, Satoshi, Kataoka, Yu
Published in Circulation (New York, N.Y.) (19.11.2019)
Published in Circulation (New York, N.Y.) (19.11.2019)
Get full text
Journal Article
Loading…
Abstract 170: Statin Therapy Increases Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Hypercholesterolemic Subjects
Qamar, Arman, Ferguson, Jane, Khera, Amit, DerOhannessian, Stephanie, Wolfe, Megan, Ky, Bonnie, Rader, Daniel
Published in Arteriosclerosis, thrombosis, and vascular biology (01.05.2012)
Published in Arteriosclerosis, thrombosis, and vascular biology (01.05.2012)
Get full text
Journal Article
Loading…
A RANDOMIZED STUDY OF THE RELATIVE BIOAVAILABILITY, PHARMACODYNAMICS, AND SAFETY OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, AFTER SINGLE SUBCUTANEOUS ADMINISTRATION AT THREE DIFFERENT INJECTION SITES IN HEALTHY SUBJECTS
Lunven, Catherine, Paehler, Tobias, Lewanczyk, Pascale, Poitiers, Franck, Brunet, Aurelie, Rey, Jacques, Hanotin, Corinne, Sasiela, Bill
Published in Journal of the American College of Cardiology (01.04.2014)
Published in Journal of the American College of Cardiology (01.04.2014)
Get full text
Journal Article
Loading…
EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240)
Ballantyne, Christie M., Neutel, Joel, Cropp, Anne, Duggan, William, Wang, Ellen, Plowchalk, David, Sweeney, Kevin, Kaila, Nitin, Vincent, John, Bays, Harold
Published in Journal of the American College of Cardiology (01.04.2014)
Published in Journal of the American College of Cardiology (01.04.2014)
Get full text
Journal Article
Loading…
EFFECTS OF RN316 (PF-04950615), A HUMANIZED IGG2[delta]A MONOCLONAL ANTIBODY BINDING PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9, ON LIPOPROTEIN PARTICLES IN HYPERCHOLESTEROLEMIC SUBJECTS
Wan, Hong, Gumbiner, Barry, Joh, Tenshang, Udata, Chandrasekhar, gues, Philippe, Garzone, Pamela D
Published in Journal of the American College of Cardiology (12.03.2013)
Published in Journal of the American College of Cardiology (12.03.2013)
Get full text
Journal Article